Winfield Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $1.1M | Sell |
21,247
-310
| -1% | -$16.1K | 0.4% | 61 |
|
|
2021
Q4 | $1.27M | Buy |
21,557
+200
| +0.9% | +$9.91K | 0.42% | 59 |
|
|
2021
Q3 | $919K | Buy |
21,357
+375
| +2% | +$16.6K | 0.34% | 67 |
|
|
2021
Q2 | $822K | Buy |
20,982
+1,235
| +6% | +$48K | 0.3% | 74 |
|
|
2021
Q1 | $715K | Buy |
19,747
+1,205
| +6% | +$42.8K | 0.29% | 73 |
|
|
2020
Q4 | $683K | Sell |
18,542
-3,093
| -14% | -$113K | 0.29% | 75 |
|
|
2020
Q3 | $753K | Buy |
21,635
+5,575
| +35% | +$195K | 0.36% | 62 |
|
|
2020
Q2 | $498K | Buy |
+16,060
| New | +$546K | 0.26% | 78 |
|
|
2020
Q1 | – | Sell |
-9,140
| Closed | -$340K | – | 141 |
|
|
2019
Q4 | $340K | Sell |
9,140
-3,268
| -26% | -$116K | 0.16% | 98 |
|
|
2019
Q3 | $423K | Sell |
12,408
-6,640
| -35% | -$241K | 0.21% | 85 |
|
|
2019
Q2 | $783K | Hold |
19,048
| – | – | 0.41% | 58 |
|
|
2019
Q1 | $768K | Hold |
19,048
| – | – | 0.41% | 56 |
|
|
2018
Q4 | $789K | Buy |
19,048
+2,635
| +16% | +$109K | 0.48% | 50 |
|
|
2018
Q3 | $686K | Hold |
16,413
| – | – | 0.34% | 61 |
|
|
2018
Q2 | $565K | Buy |
16,413
+422
| +3% | +$14.4K | 0.3% | 68 |
|
|
2018
Q1 | $538K | Sell |
15,991
-2,577
| -14% | -$88.6K | 0.29% | 77 |
|
|
2017
Q4 | $640K | Buy |
18,568
+457
| +3% | +$15.6K | 0.32% | 73 |
|
|
2017
Q3 | $613K | Sell |
18,111
-1,316
| -7% | -$42.3K | 0.32% | 71 |
|
|
2017
Q2 | $620K | Buy |
19,427
+241
| +1% | +$7.6K | 0.34% | 68 |
|
|
2017
Q1 | $623K | Sell |
19,186
-597
| -3% | -$18.8K | 0.35% | 69 |
|
|
2016
Q4 | $609K | Sell |
19,783
-577
| -3% | -$17.6K | 0.37% | 72 |
|
|
2016
Q3 | $655K | Buy |
20,360
+3,162
| +18% | +$106K | 0.41% | 68 |
|
|
2016
Q2 | $575K | Sell |
17,198
-34
| -0.2% | -$1.08K | 0.37% | 69 |
|
|
2016
Q1 | $485K | Buy |
17,232
+1,339
| +8% | +$38.2K | 0.33% | 71 |
|
|
2015
Q4 | $487K | Buy |
15,893
+632
| +4% | +$19.9K | 0.33% | 69 |
|
|
2015
Q3 | $455K | Sell |
15,261
-3,349
| -18% | -$107K | 0.34% | 66 |
|
|
2015
Q2 | $592K | Sell |
18,610
-527
| -3% | -$17.2K | 0.41% | 64 |
|
|
2015
Q1 | $632K | Sell |
19,137
-252
| -1% | -$8.01K | 0.44% | 63 |
|
|
2014
Q4 | $573K | Sell |
19,389
-8,353
| -30% | -$240K | 0.42% | 68 |
|
|
2014
Q3 | $778K | Sell |
27,742
-340
| -1% | -$9.54K | 0.58% | 54 |
|
|
2014
Q2 | $790K | Sell |
28,082
-3,460
| -11% | -$98.6K | 0.57% | 53 |
|
|
2014
Q1 | $961K | Sell |
31,542
-671
| -2% | -$20K | 0.79% | 41 |
|
|
2013
Q4 | $936K | Buy |
+32,213
| New | +$938K | 0.77% | 41 |
|
Other funds holding PFE
Winfield Associates's PFE Position: Q1 2022 in Review
Winfield Associates reduced its Pfizer (PFE) stake by 1.4% in Q1 2022, selling an estimated $16.1K and leaving 21,247 shares worth $1.1M. The position accounts for 0.4% of the portfolio, ranked #61.
Winfield Associates first reported a position in PFE in Q4 2013 and has held it in 33 quarters since. The position peaked at $1.27M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Winfield Associates held 21,247 shares of Pfizer worth $1.1M as of Q1 2022.
- Winfield Associates sold 310 Pfizer shares in Q1 2022, an estimated $16.1K.
- Pfizer made up 0.4% of Winfield Associates's portfolio in Q1 2022, its #61 holding.
- Winfield Associates first reported a position in Pfizer in Q4 2013 and has held it in 33 quarters since.
- Winfield Associates's Pfizer position peaked at $1.27M in Q4 2021.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.